DK3119911T3 - Forbindelser til anvendelse til behandling af alzheimers sygdom hos apoe4+/+ patienter - Google Patents
Forbindelser til anvendelse til behandling af alzheimers sygdom hos apoe4+/+ patienter Download PDFInfo
- Publication number
- DK3119911T3 DK3119911T3 DK15764560.7T DK15764560T DK3119911T3 DK 3119911 T3 DK3119911 T3 DK 3119911T3 DK 15764560 T DK15764560 T DK 15764560T DK 3119911 T3 DK3119911 T3 DK 3119911T3
- Authority
- DK
- Denmark
- Prior art keywords
- apoe4
- alzheimer
- patients
- disease
- compounds
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/05—Dipeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H10/00—ICT specially adapted for the handling or processing of patient-related medical or healthcare data
- G16H10/20—ICT specially adapted for the handling or processing of patient-related medical or healthcare data for electronic clinical trials or questionnaires
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H20/00—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance
- G16H20/10—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H20/00—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance
- G16H20/70—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to mental therapies, e.g. psychological therapy or autogenous training
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H40/00—ICT specially adapted for the management or administration of healthcare resources or facilities; ICT specially adapted for the management or operation of medical equipment or devices
- G16H40/20—ICT specially adapted for the management or administration of healthcare resources or facilities; ICT specially adapted for the management or operation of medical equipment or devices for the management or administration of healthcare resources or facilities, e.g. managing hospital staff or surgery rooms
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Biomedical Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Molecular Biology (AREA)
- Analytical Chemistry (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Physics & Mathematics (AREA)
- Pathology (AREA)
- Gastroenterology & Hepatology (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Cell Biology (AREA)
- General Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- General Engineering & Computer Science (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201461968595P | 2014-03-21 | 2014-03-21 | |
PCT/US2015/022058 WO2015143447A2 (en) | 2014-03-21 | 2015-03-23 | Methods for treating neurological disorders |
Publications (1)
Publication Number | Publication Date |
---|---|
DK3119911T3 true DK3119911T3 (da) | 2023-10-30 |
Family
ID=54145492
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK15764560.7T DK3119911T3 (da) | 2014-03-21 | 2015-03-23 | Forbindelser til anvendelse til behandling af alzheimers sygdom hos apoe4+/+ patienter |
Country Status (18)
Country | Link |
---|---|
US (3) | US10471029B2 (da) |
EP (2) | EP3119911B1 (da) |
JP (4) | JP6588962B2 (da) |
KR (2) | KR102448386B1 (da) |
CN (1) | CN106170563A (da) |
AU (1) | AU2015230972B2 (da) |
CA (1) | CA2941415A1 (da) |
DK (1) | DK3119911T3 (da) |
ES (1) | ES2960625T3 (da) |
FI (1) | FI3119911T3 (da) |
HR (1) | HRP20231172T1 (da) |
HU (1) | HUE063369T2 (da) |
LT (1) | LT3119911T (da) |
PL (1) | PL3119911T3 (da) |
PT (1) | PT3119911T (da) |
RS (1) | RS64744B1 (da) |
SI (1) | SI3119911T1 (da) |
WO (1) | WO2015143447A2 (da) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2017044840A1 (en) * | 2015-09-10 | 2017-03-16 | Alzheon, Inc. | Methods of treating neurodegenerative disorders in a particular patient population |
CN109475575A (zh) * | 2016-07-13 | 2019-03-15 | 米托斯株式会社 | 包含氢作为有效成分的用于预防或治疗轻度认知障碍或认知症的组合物 |
CN114805211A (zh) | 2017-03-21 | 2022-07-29 | 润佳(苏州)医药科技有限公司 | 同位素富集3-氨基-1-丙磺酸衍生物、药物组合物及其用途 |
CN110003058B (zh) | 2018-01-04 | 2022-01-25 | 润佳(苏州)医药科技有限公司 | 3-((l-缬氨酰基)氨基)-3,3-二氘-1-丙磺酸晶型、制备方法及用途 |
CN110668980A (zh) * | 2018-07-03 | 2020-01-10 | 浙江京新药业股份有限公司 | 一种2-取代的高牛磺酸衍生物 |
AU2019314323A1 (en) * | 2018-08-01 | 2021-03-18 | Alzheon, Inc. | Sulfopropanoic acid derivatives for treating neurodegenerative disorders |
SG11202100767XA (en) * | 2018-08-01 | 2021-02-25 | Alzheon Inc | Methods for treating neurodegenerative disorders |
CN111170901A (zh) * | 2018-11-13 | 2020-05-19 | 润佳(苏州)医药科技有限公司 | 3-((l-缬氨酰基)氨基)-1-丙磺酸晶型、制备方法及其用途 |
CA3144008A1 (en) | 2019-06-17 | 2020-12-24 | Alzheon, Inc. | Methods for treating neurodegenerative disorders |
CN116059192A (zh) | 2019-11-13 | 2023-05-05 | 润佳(苏州)医药科技有限公司 | 同位素富集的3-氨基-1-丙磺酸及其衍生物的用途 |
WO2023212289A1 (en) | 2022-04-28 | 2023-11-02 | Alzheon, Inc. | Tramiprosate for treating apoe4-related diseases |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5698155A (en) | 1991-05-31 | 1997-12-16 | Gs Technologies, Inc. | Method for the manufacture of pharmaceutical cellulose capsules |
ATE262592T1 (de) * | 1992-10-13 | 2004-04-15 | Univ Duke | Verfahren zum nachweis der alzheimer krankheit |
US20050031651A1 (en) | 2002-12-24 | 2005-02-10 | Francine Gervais | Therapeutic formulations for the treatment of beta-amyloid related diseases |
US20070010573A1 (en) * | 2003-06-23 | 2007-01-11 | Xianqi Kong | Methods and compositions for treating amyloid-related diseases |
US20060079578A1 (en) * | 2003-06-23 | 2006-04-13 | Julie Laurin | Pharmaceutical formulations of amyloid inhibiting compounds |
US20050142191A1 (en) | 2003-06-23 | 2005-06-30 | Neurochem (International) Limited | Pharmaceutical formulations of amyloid inhibiting compounds |
JP2007502418A (ja) | 2003-08-11 | 2007-02-08 | カリフォルニア・インスティテュート・オブ・テクノロジー | 微量流体大規模集積 |
PL3851447T3 (pl) | 2006-10-12 | 2024-03-04 | Bellus Health Inc. | Sposoby, związki, kompozycje i nośniki dostarczające kwas 3-amino-1-propanosulfonowy |
CN102838532A (zh) | 2006-11-24 | 2012-12-26 | Ac免疫有限公司 | 用于治疗与淀粉样物质或淀粉样蛋白有关的疾病的吡唑胺和噻唑胺衍生物 |
WO2012006329A2 (en) * | 2010-07-06 | 2012-01-12 | Genomind, Llc | Apoe4 and apoj biomarker-based prevention and treatment of dementia |
US10449177B2 (en) | 2010-08-19 | 2019-10-22 | Buck Institute For Research On Aging | Methods of treating mild cognitive impairment (MCI) and related disorders |
HUE044737T2 (hu) | 2013-05-06 | 2019-11-28 | Baxalta Inc | Alzheimer-kór szubpopulációk kezelése egyesített immunglubulin G-vel |
KR20230056800A (ko) * | 2014-02-08 | 2023-04-27 | 제넨테크, 인크. | 알츠하이머 질환을 치료하는 방법 |
WO2017044840A1 (en) | 2015-09-10 | 2017-03-16 | Alzheon, Inc. | Methods of treating neurodegenerative disorders in a particular patient population |
US20180250249A1 (en) | 2016-02-02 | 2018-09-06 | Alzheon, Inc. | Methods of treating neurodegenerative disorders in a particular population |
-
2015
- 2015-03-23 WO PCT/US2015/022058 patent/WO2015143447A2/en active Application Filing
- 2015-03-23 JP JP2017501145A patent/JP6588962B2/ja active Active
- 2015-03-23 FI FIEP15764560.7T patent/FI3119911T3/fi active
- 2015-03-23 KR KR1020167027090A patent/KR102448386B1/ko active IP Right Grant
- 2015-03-23 PL PL15764560.7T patent/PL3119911T3/pl unknown
- 2015-03-23 DK DK15764560.7T patent/DK3119911T3/da active
- 2015-03-23 US US15/127,565 patent/US10471029B2/en active Active
- 2015-03-23 AU AU2015230972A patent/AU2015230972B2/en active Active
- 2015-03-23 EP EP15764560.7A patent/EP3119911B1/en active Active
- 2015-03-23 CA CA2941415A patent/CA2941415A1/en active Pending
- 2015-03-23 LT LTEPPCT/US2015/022058T patent/LT3119911T/lt unknown
- 2015-03-23 CN CN201580015086.8A patent/CN106170563A/zh active Pending
- 2015-03-23 RS RS20230993A patent/RS64744B1/sr unknown
- 2015-03-23 KR KR1020227033161A patent/KR102645633B1/ko active IP Right Grant
- 2015-03-23 ES ES15764560T patent/ES2960625T3/es active Active
- 2015-03-23 SI SI201531967T patent/SI3119911T1/sl unknown
- 2015-03-23 HU HUE15764560A patent/HUE063369T2/hu unknown
- 2015-03-23 EP EP23189240.7A patent/EP4289820A3/en active Pending
- 2015-03-23 HR HRP20231172TT patent/HRP20231172T1/hr unknown
- 2015-03-23 PT PT157645607T patent/PT3119911T/pt unknown
-
2019
- 2019-01-29 JP JP2019012873A patent/JP2019065044A/ja not_active Withdrawn
- 2019-09-13 US US16/570,487 patent/US20200101031A1/en not_active Abandoned
-
2020
- 2020-04-02 JP JP2020066670A patent/JP2020109123A/ja not_active Withdrawn
-
2022
- 2022-07-29 US US17/877,380 patent/US20230087041A1/en active Pending
- 2022-08-22 JP JP2022131705A patent/JP2022159555A/ja active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK3119911T3 (da) | Forbindelser til anvendelse til behandling af alzheimers sygdom hos apoe4+/+ patienter | |
DK3347030T3 (da) | Brug af pasteuriseret akkermansia til behandling af stofskiftesygdomme | |
MA45192A (fr) | Traitement d'association | |
DK3134386T3 (da) | Isoindolin-1-on-derivater med kolinerg muscarin-m1-receptor-positiv allosterisk modulatoraktivitet til behandling af alzheimers sygdom | |
IL285722A (en) | Methods for treating Alzheimer's disease | |
DK3212233T3 (da) | Kombinationsterapi til behandling af sygdom | |
DK3119397T3 (da) | Heterocykliske forbindelser til anvendelse i behandling af PI3K-gamma-medierede lidelser | |
GB201500314D0 (en) | Pharmaceutical formulations for the treatment of pulmonary arterial hypertension | |
DK3240612T3 (da) | Fremgangsmåder til behandling af nethindesygdomme | |
DK3474802T3 (da) | Medicinsk forbinding | |
DK3265087T3 (da) | Fremgangsmåde til behandling med tradipitant | |
DK3151851T3 (da) | Ornithodoros-moubata-komplement-inhibitor til anvendelse i behandlingen af komplement-medierede sygdomme hos patienter med c5-polymorfisme | |
DK3347002T3 (da) | Behandling af alzheimers sygdom i en bestemt patientpopulation | |
DK3463351T3 (da) | Behandling til parkinsons sygdom | |
DK3149049T3 (da) | Il-22 til anvendelse til behandling af stofskiftesygdomme | |
DK3125874T3 (da) | Et terapeutisk middel til anvendelse i behandlingen af infektioner | |
HK1243709A1 (zh) | 可用於治療阿爾茨海默氏病的四氫呋喃稠合的氨基氫噻嗪衍生物 | |
DK3096775T3 (da) | SOCS-mimetika til behandling af sygdomme | |
DK3049099T3 (da) | Amyloid-beta-bindende peptider og anvendelse deraf til terapi og diagnosticering af alzheimers demens | |
DE112015002229A5 (de) | Formulierungen zur Behandlung von Hyperthyreose | |
DK3413870T3 (da) | Igmesin til anvendelse ved behandlingen af alzheimers sygdom | |
DK3518801T3 (da) | System til kirurgisk behandling | |
DK3137094T3 (da) | Behandling og forebyggelse af alzheimers sygdom (ad) | |
KR20180085033A (ko) | 피부 질환 치료용 약학적 제형 및 이의 제조 방법 | |
DK3066475T3 (da) | Biomarkører for progression af alzheimers sygdom |